https://www.selleckchem.com/pr....oducts/pf-07220060.h
correlations in other subtypes. Data about safety and efficacy of the mRNA SARS-CoV-2 vaccine in adolescents with rheumatic diseases (RD) is scarce and whether these patients generate a sufficient immune response to the vaccine remains an outstanding question. To evaluate safety and humoral and cellular immunity of the BNT162b2 vaccine in adolescents 12 to 18years with RD and immunosuppressive treatment compared with a healthy control group. Adolescents from 12 to 18years with RD followed at Hospital La Paz in Madrid (n = 4 receiv
Like
Comment
Share
